Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-02-07
2008-01-29
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S045000, C514S046000, C514S047000
Reexamination Certificate
active
07323453
ABSTRACT:
The present invention provides methods of inhibiting orthopoxvirus replication and/or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are particularly useful as inhibitors of vaccinia virus and variola virus replication and/or for the treatment of vaccinia virus and variola virus infection. The nucleoside compounds may be administered alone or in combination with other agents active against orthopoxvirus infection, in particular against vaccinia virus or variola virus infection. Another aspect of the present invention provides for the use of such nucleoside compounds in the manufacture of a medicament for the inhibition of orthopoxvirus replication and/or for the treatment of orthopoxvirus infection. Yet a further aspect of the present invention provides such nucleoside compounds for use as a medicament for the inhibition of orthopoxvirus replication and/or for the treatment of orthopoxvirus infection.
REFERENCES:
patent: 6777395 (2004-08-01), Bhat et al.
patent: 2003/0050229 (2003-03-01), Sommadossi et al.
patent: 2003/0060400 (2003-03-01), LaColla et al.
patent: WO 01/90121 (2001-11-01), None
patent: WO 01/92282 (2001-12-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/32920 (2002-04-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 2004/000858 (2003-12-01), None
patent: WO 2004/046331 (2004-06-01), None
Neyts et al. Antimicrobial Agents and Chemotherapy (2001), vol. 45, pp. 84-87.
De Clerq Clinical Microbiology Reviews (2001), vol. 14, pp. 382-397.
Per Hoffmann, et al., “Recent patents on experimental therapy for hepatitis C virus infection (1999-2002)”, Expert Opin. Ther. Patents [2003] pp. (1707-1723), vol. 13, No. 11.
Bera Sanjib
Eldrup Anne B.
LaFemina Robert L.
Olsen David B.
Durette Philippe L.
Heber Sheldon O.
Isis Pharmaceuticals , Inc.
Lewis Patrick
Merck & Co. , Inc.
LandOfFree
Methods of inhibiting orthopoxvirus replication with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting orthopoxvirus replication with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting orthopoxvirus replication with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3962411